Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

22.04.22	Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer (GlobeNewswire)
14.04.22	Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio (GlobeNewswire)
06.04.22	Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR) (GlobeNewswire)
06.04.22	FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS) (GlobeNewswire)
05.04.22	Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility (GlobeNewswire)
04.04.22	Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity (GlobeNewswire)
04.04.22	Novartis gibt neue Organisationsstruktur bekannt für schnelleres Wachstum, eine stärkere Pipeline und höhrere Produktivität (GlobeNewswire)
25.03.22	Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease (GlobeNewswire)
25.03.22	Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe (GlobeNewswire)
23.03.22	Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer (GlobeNewswire)
14.03.22	Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce (GlobeNewswire)
14.03.22	Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection (GlobeNewswire)
04.03.22	Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut (GlobeNewswire)
04.03.22	Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting (GlobeNewswire)
18.02.22	Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine (GlobeNewswire)
02.02.22	Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021 (GlobeNewswire)
02.02.22	Novartis erzielt 2021 ein Umsatzwachstum im mittleren einstelligen Bereich, verbessert die Margen und treibt die solide Pipeline voran (GlobeNewswire)
10.01.22	Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 (GlobeNewswire)
04.01.22	Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent (GlobeNewswire)
23.12.21	Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis (GlobeNewswire)
22.12.21	FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year (GlobeNewswire)
22.12.21	Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness (GlobeNewswire)
22.12.21	Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA (GlobeNewswire)
20.12.21	Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA (GlobeNewswire)
20.12.21	Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab (GlobeNewswire)
20.12.21	Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU) (GlobeNewswire)
16.12.21	Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline (GlobeNewswire)
16.12.21	Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline (GlobeNewswire)
13.12.21	Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021 (GlobeNewswire)
11.12.21	Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia (GlobeNewswire)
11.12.21	Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up (GlobeNewswire)
10.12.21	Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i (GlobeNewswire)
08.12.21	New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer (GlobeNewswire)
02.12.21	Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms (GlobeNewswire)
04.11.21	New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio (GlobeNewswire)
04.11.21	Novartis verkauft ihre Roche-Beteiligung in einer bilateralen Transaktion an Roche (GlobeNewswire)
04.11.21	Novartis to sell its Roche stake in a bilateral transaction to Roche (GlobeNewswire)
29.10.21	FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia (GlobeNewswire)
26.10.21	Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz (GlobeNewswire)
26.10.21	Novartis erzielt im dritten Quartal solide Ergebnisse – mit starkem Wachstum bei Innovative Medicines. Das Unternehmen kündigt eine strategische Überprüfung von Sandoz an (GlobeNewswire)
25.10.21	Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer (GlobeNewswire)
19.10.21	Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer (GlobeNewswire)
11.10.21	Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics (GlobeNewswire)
01.10.21	Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs (GlobeNewswire)
30.09.21	Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions (GlobeNewswire)
19.09.21	Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer (GlobeNewswire)
17.09.21	Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS) (GlobeNewswire)
17.09.21	Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021 (GlobeNewswire)
08.09.21	Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine (GlobeNewswire)
30.08.21	Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	545.40	2.71 %	K V
Logitech Intl	70.10	2.34 %	K V
Givaudan	3’919.00	1.45 %	K V
Swiss Re	126.85	0.71 %	K V
Roche Hldg G	250.90	0.68 %	K V
Holcim	89.58	-0.56 %	K V
Swisscom	505.00	-0.59 %	K V
Sonova Hldg	301.50	-0.63 %	K V
Nestle	75.94	-0.76 %	K V
CieFinRichemont	117.00	-1.35 %	K V

mehr

13:34		Bayer-Aktie in Rot: FDA erweitert Zulassung für Bayer-Krebsmedikament Nubeqa
12:26		Donnerstagshandel in Zürich: SPI zeigt sich mittags schwächer
12:26		Zuversicht in Zürich: SMI legt zu
12:26		Freundlicher Handel: DAX notiert am Donnerstagmittag im Plus
12:26		Gewinne in Zürich: So performt der SLI am Mittag
12:26		LUS-DAX-Handel aktuell: LUS-DAX liegt mittags im Minus
12:26		Anleger in Frankfurt halten sich zurück: SDAX verliert am Mittag
12:26		Schwacher Handel: Euro STOXX 50 am Donnerstagmittag in der Verlustzone